Abstract:Chenglong Sun, 1– 3, * Liping Zhang, 4, * Wei Zhang, 4, * Yu Liu, 3, 5 Bin Chen, 3 Sha Zhao, 3 Wei Li, 3 Lei Wang, 3 Lingyun Ye, 3 Keyi Jia, 3, 5 Hao Wang, 3, 5 Chunyan Wu, 4 Yayi He, 3 Caicun Zhou 3 1 Medical College of Soochow University, Suzhou 215123, Jiangsu, People's Republic of China; 2 Anhui No.2 Provincial People's Hospital, Hefei 230041, Anhui, People's Republic of China; 3 Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, People's Republic of China; 4 Pathology Department, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, People's Republic of China; 5 Medical School, Tongji University, Shanghai 200433, People's Republic of China *These authors contributed equally to this work Correspondence: Yayi He Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, No. 507 Zhengmin Road, Shanghai 200433, People's Republic of China Tel +13818828623 Email 2250601@qq.com Caicun Zhou Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, No. 507 Zhengmin Road, Shanghai 200433, People's Republic of China Tel +13301825532 Email caicunzhou@gmail.com Introduction: Immune therapy has shown good results in small-cell lung cancer (SCLC), but the impact of immune microenvironment of the disease is unclear. In this work, we detected expression of programmed death 1 (PD-1), PD-ligand 1 (PD-L1), and other immune biomarkers of cancer. We also analyzed the correlations between these markers and survival in SCLC. Patients and Methods: Protein expression of PD-1, PD-L1, PD-L2, CD3, CD4, CD8, and FOXP3 was analyzed in surgical tissues from 102 SCLC patients by immunohistochemistry. Results: Positive expression of PD-1 on tumor-infiltrating lymphocytes (TILs) was found in 40.2% of patients; 37.3% of patients showed positive expression of PD-L1 on TILs; and 3.9% showed positive expression of PD-L1 on tumor cells. PD-L2 protein was not expressed on tumor cells or TILs. Survival analysis showed that positive expression of PD-L1 on TILs was correlated with longer relapse-free survival (RFS) (p=0.004). Positive expression of PD-1 combined with a high ratio of lymphocytes (CD3, p=0.004; CD4, p=0.011; CD8, p=0.009; FOXP3, p=0.009) was associated with significantly better RFS than negative expression of PD-1 combined with a lower ratio of lymphocytes. Positive expression of PD-L1 combined with a high ratio of lymphocytes (CD3, p< 0.001; CD4, p=0.001; CD8, p=0.002; FOXP3, p=0.001) was associated with significantly better RFS than negative expression of PD-L1 combined with a lower ratio of lymphocytes. All patients' stage were between I and III. Conclusion: PD-1 and PD-L1 expression might be good prognostic factors in SCLC. Keywords: small-cell lung cancer, SCLC, programmed death-1, PD-1, programmed death-ligand 1, PD-L1, programmed death-ligand 2, PD-L2, tumor-infiltrating lymphocytes, TILs

Stromal PD L1–positive regulatory T cells and PD 1–positive CD8 positive T cells define the response of different subsets of non–small cell lung Cancer to PD 1/PD L1 blockade …

Stromal PD-L1+regulatory T cells and PD-1+CD8+ T cells define the response of different subsets of non-small-cell lung cancer to PD-1/PD-L1 blockade immunotherapy.

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

T lymphocyte subsets and PD-1 expression on lymphocytes in peripheral blood of patients with non-small cell lung cancer

Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy

Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8+ T Cells in Non-Small Cell Lung Cancer

Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer

Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer

PD-1(+) IFN-gamma(+) subset of CD8(+) T cell in circulation predicts response to anti-PD-1 therapy in NSCLC

Proliferation of Pd-1+Cd8 T Cells in Peripheral Blood after Pd-1-Targeted Therapy in Lung Cancer Patients

PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort

Expression of PD-1 and PD-L1 on Tumor-Infiltrating Lymphocytes Predicts Prognosis in Patients with Small-Cell Lung Cancer

Evaluating U.S. Electoral Representation with a Joint Statistical Model of Congressional Roll-Calls, Legislative Text, and Voter Registration Data

Circulating PD-L1 in NSCLC Patients and the Correlation Between the Level of PD-L1 Expression and the Clinical Characteristics.

Genomic correlates of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients

Features in genomics and tumor immune microenvironment in NSCLC treated with neoadjuvant PD-1 blockade.

PD-L1 Expression in Chinese Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multi-Center Retrospective Observational Study

Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatment

Barrett’s Metaplasia and Colonic Neoplasms: A Significant Association in a 203,534-Patient Study

Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer

Haptic design for continuous‐loop, scleral fixation of posterior chamber lens